Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update.
Qyuns Therapeutics Co., Ltd. has utilized its surplus cash to enter into two new subscription agreements for wealth management products with PDB, a listed commercial bank, involving a total principal amount of RMB 160 million with low-risk, principal-guaranteed floating-yield returns and October 2024 maturity. The biotech company, focusing on autoimmune and allergic diseases, strategically managed its funds without affecting its IPO proceeds, reflecting a proactive approach to capital management.
For further insights into HK:2509 stock, check out TipRanks’ Stock Analysis page.
